Irbesartan
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Irbesartan: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Irbesartan is an angiotensin II receptor blocker, marketed in South Africa as an oral tablet. The SAHPRA indication text was not supplied, so its original use is taken from general drug-class knowledge. The TxGNN model predicts it may be useful for malignant renovascular hypertension, but there are currently 0 clinical trials and 0 relevant publications supporting this. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (general class knowledge; not stated in the supplied SAHPRA data) |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the supplied pack. Irbesartan belongs to the angiotensin II type 1 (AT1) receptor blocker class. Renovascular hypertension is driven largely by activation of the renin-angiotensin system, so blocking this pathway is biologically plausible.
However, the 99.31% TxGNN score is a computational prediction only. Several cautions apply:
- Malignant (accelerated) hypertension is a hypertensive emergency. It is normally managed with titratable IV agents, so an oral ARB is unlikely to be first-line.
- ARBs carry a known risk of acute decline in kidney function in bilateral renal artery stenosis or stenosis in a solitary kidney. This is the very population in which renovascular hypertension occurs.
- The related prediction “malignant hypertensive renal disease” has an identical score. The two are probably correlated, not independent evidence.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR, PACTR or ICTRP records were retrieved for this drug-indication pair.
Literature Evidence
Currently no related literature available for malignant renovascular hypertension.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 46/7.1.3/0124 | Jubitan | Tablet | Not stated in supplied data |
| Reg. No. 42/7.1.3/0116 | Co Irbewin 300/25 | Tablet | Not stated in supplied data |
| Reg. No. 45/7.1.3/0073 | Isart Co 150 | Tablet | Not stated in supplied data |
All three products are oral tablets. The “Co” product names suggest fixed-dose combinations. Confirm the exact composition in the SAHPRA Professional Information (PI). Essential Medicines List (EML) status was not provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Class-level concerns raised in the prediction assessment for this setting:
- Acute kidney injury and hyperkalaemia risk in patients with severe hypertensive renal involvement.
- Acute renal function decline in bilateral renal artery stenosis or stenosis in a solitary kidney.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a plausible mechanism, but there are no trials or relevant literature. The condition is an emergency where oral ARBs are not standard first-line therapy, and renal safety concerns are significant.
To proceed, the following is needed:
- SAHPRA PI warnings, contraindications and approved indication text, so safety screening can begin.
- Mechanism of action data from DrugBank to support the mechanistic-link analysis.
- Targeted searches for irbesartan or ARB studies in renovascular and malignant hypertension. The current literature hits are unrelated hypoxia papers.
- A clinical assessment of whether an oral ARB has any role in this emergency setting, with particular attention to renal artery stenosis.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.